<DOC>
	<DOCNO>NCT00008099</DOCNO>
	<brief_summary>RATIONALE : Vaccines may help body build effective immune response kill tumor cell . PURPOSE : This phase I trial study side effect best dose vaccine therapy treat patient resect locally advanced unresectable pancreatic cancer .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Resected Locally Advanced Unresectable Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety toxicity vaccination MUC-1 antigen immunologic adjuvant SB AS-2 patient resect locally advanced unresectable pancreatic cancer . II . Determine maximum tolerate dose and/or recommend phase II dose MUC-1 antigen patient population . III . Determine qualitative quantitative tumor response treatment patient . IV . Determine disease-free survival resect patient , progression-free survival locally advance unresectable patient , overall survival patient receive treatment . OUTLINE : This dose escalation study MUC-1 antigen . Patients receive vaccination MUC-1 antigen immunologic adjuvant SB AS-2 intramuscularly day 1 . Treatment repeat every 3 week total 3 course absence disease progression unacceptable toxicity . Beginning 1 year last vaccination , patient without recurrent disease may receive booster vaccine annually . Cohorts 4 8 patient receive escalate dos MUC-1 antigen maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 4 2 8 patient experience dose-limiting toxicity . Patients follow 2 week . PROJECTED ACCRUAL : A total 15-20 patient accrue study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm resect locally advanced unresectable pancreatic cancer No metastases PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ECOG 02 Life expectancy : At least 4 month Hematopoietic : WBC great 3,500/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin great 2.0 mg/dL Renal : Creatinine great 1.5 mg/dL Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective double barrier contraception 1 week , , least 2 week study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : No concurrent glucocorticosteroids Radiotherapy : No prior radiotherapy Surgery : At least 3 week since prior resection pancreatic cancer Other : No concurrent nonsteroidal antiinflammatory drug ( NSAIDs )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>stage I pancreatic cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>